Diana Crisan, MD
Clinical Neurophysiology · Suffern, NYNPI 1669796009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 29.5% of the total. Reporting peaked in 2022 at $770 and has fallen 78.0% since, to $170 in 2024.
Across 104 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$623
- Biogen$304
- UCB, Inc.$261
- Biohaven Pharmaceutical Holding Company Ltd.$119
- Biohaven Pharmaceuticals, Inc.$94
- DJO, LLC$87
- plus $621 from 19 others
What the payments were for
- Food & beverage$2,09099%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $623 |
| Biogen | 15 | $304 |
| UCB, Inc. | 12 | $261 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $119 |
| Biohaven Pharmaceuticals, Inc. | 4 | $94 |
| DJO, LLC | 1 | $87 |
| Upsher-smith Laboratories LLC | 3 | $71 |
| Pfizer | 4 | $65 |
| Novartis | 3 | $64 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 1 | $34 |
| Lundbeck LLC | 2 | $33 |
| Avion Pharmaceuticals | 2 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Argenx US, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| CSL Behring | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Livanova USA, Inc. | 1 | $13 |
| GE HealthCare | 1 | $13 |
How this compares
$2,110 in reported general payments places this provider in the 55th percentile of 35 clinical neurophysiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 18 | $11,697 |
| RytaryCarbidopa/Levodopa | 13 | $6,369 |
| Memantine Hcl ErMemantine Hcl | 32 | $4,619 |
| Memantine Hcl | 29 | $1,593 |
| Donepezil Hcl | 37 | $885 |
| Gabapentin | 21 | $637 |
| RivastigmineRivastigmine Tartrate | 11 | $425 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 13 | $315 |
| Quetiapine Fumarate | 20 | $262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric | $623 | $11,69718 claims |
| Amneal Pharmaceuticals LLCRytary | $30 | $6,36913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 35 clinical neurophysiology providers in New York.
Other clinical neurophysiology in Suffern
- Alcibiades RodriguezNew York$714K
- Farhad Kadkhodaei ElyaderaniBronx$156K
- Jessica Robinson-PappNew York$28K
- Mohini GurmeWest Nyack$13K
- Cecily AntoHauppauge$11K
- Itzhak HaimovicGreat Neck$7K
- Madeline FieldsNew York$5K
- Agnieszka KokoszkaNew York$5K
- Justin SilversteinHauppauge$3K
- Simona ProteasaGreat Neck$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.